Advanced preclinical development of a solid tumour-tailored gastric cancer therapy

针对实体瘤的胃癌治疗的高级临床前开发

• 批准号: 10015613
• 金额: $ 158.28万
• 依托单位: ANTIKOR BIOPHARMA LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10015613
• 关键词: Advanced; preclinical; development; solid; tumour

Antikor Biopharma is pioneering an innovative drug delivery platform called OptiLink. It harnesses the immune system by using tumour-seeking antibodies to specifically deliver potent cytotoxic payloads to tumours. Unlike its competitors, who use full antibody-drug conjugates (ADCs), Antikor's technology enables much smaller fragment-drug conjugates (FDCs) to be developed. These have many advantages: FDC products potentially have a higher therapeutic index for cancer therapy as they are more potent, can be dosed more aggressively because they clear from normal tissues more quickly and penetrate rapidly and deeply into tumours, enabling faster tumour destruction. Antikor is developing an FDC for gastric cancer which promises to overcome the challenges in treating this disease. This project entails the advanced preclinical development and manufacturing process optimisation and CMO-technology transfer to support regulatory submissions for future clinical development.

安提科生物医药公司正在开创一种名为OptiLink的创新药物输送平台。它通过使用寻找肿瘤的抗体来特异性地将有效的细胞毒有效载荷递送到肿瘤来利用免疫系统。与使用完全抗体-药物结合物(ADC)的竞争对手不同，安提科的技术能够开发出更小的片段-药物结合物(FDC)。这些产品有许多优点：FDC产品可能具有更高的癌症治疗指数，因为它们更有效，可以更积极地给药，因为它们更快地从正常组织中清除，并迅速和深入到肿瘤中，使肿瘤能够更快地被破坏。安提科正在开发一种治疗胃癌的FDC，它有望克服治疗这种疾病的挑战。该项目需要先进的临床前开发和制造流程优化以及CMO技术转让，以支持未来临床开发的监管提交。